Results 51 to 60 of about 22,249,811 (294)
, 2022 PurposeWe aimed to investigate the restoration of CD8+PD-1+ T cells through adoptive T-cell therapy (ACT) in relation to the prognosis and the therapeutic response to anti-PD-1 in patients with advanced pancreatic cancer (APC).MethodsA total of 177 adult
Qian Zhu (191342) +11 more
core +1 more source
, 2023 Validation of IRS to stratify anti-PD-(L)1 monotherapy benefit in patients with advanced solid tumors. A, Clinical characteristics of the anti-PD-(L)1 monotherapy validation cohort are shown in an alluvial diagram.
Marc Matrana (16484182) +37 more
core +1 more source
PD-1 as an Immune Modulatory Receptor [PDF]
The Cancer Journal, 2014 Programmed cell death 1 (PD-1) is an inducible immune modulatory receptor. Upon interaction with its ligands B7 homolog 1 (PD-L1) and B7-DC (PD-L2), PD-1 plays important roles in negative regulation of T cell responses to antigen stimulation and maintaining peripheral tolerance.
Sheng, Yao, Lieping, Chen
openaire +2 more sources
PD-1 blockade enhances susceptibility to Brucella.
, 2023 WT and/or μMT mice (n = 4-5/treatment) were treated with PD-1 blocking antibody, CD4+ T cell depleting antibody, PD-1 blocking and CD4-depleting antibody, or isotype control. (A & C) Splenic bacterial loads in IgG and PD-1 blocked WT (A) or μMT (C) mice.
Jerod Skyberg (17002171) +7 more
core +1 more source
Machine and deep learning driven models for the design of heat exchangers with micro-finned tubes
Energy and AIThe design of micro-finned tube heat exchangers is a complex task due to intricate geometry, heat transfer goals, material selection, and manufacturing challenges. Nowadays, mathematical models provide valuable insights, aid in optimization, and allow us
Emad Efatinasab +3 more
doaj +1 more source
Antibodies, 2022 This study aimed to investigate PD-L1 and PD-1 expression in circulating CD20+ cells in diffuse larger B-cell lymphoma (DLBCL) and to evaluate the predictive and diagnostic performance of PD-L1 versus PD-1 expression in circulating CD20+ cells in DLBCL ...
Manal Mohamed Saber
doaj +1 more source
Immunotherapy protocols in lung cancer
Cancer Research, Statistics, and Treatment, 2018 Immunotherapy has emerged as a valuable treatment option in many advanced malignancies (especially lung cancer). The PD-1 inhibitors (nivolumab and pembrolizumab) and the PD-L1 inhibitors (durvalumab and atezolizumab) have been approved for use in ...
Nandini Menon, Sharada Mailankody
doaj +1 more source
Nature Immunology, 2019 Understanding resistance to antibody to programmed cell death protein 1 (PD-1; anti-PD-1) is crucial for the development of reversal strategies. In anti-PD-1-resistant models, simultaneous anti-PD-1 and vaccine therapy reversed resistance, while PD-1 blockade before antigen priming abolished therapeutic outcomes.
Vivek Verma +27 more
openaire +3 more sources
Cell, 2015 Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung cancer.
openaire +2 more sources
PD-1/PD-L1 axis in organ fibrosis
Frontiers in Immunology, 2023 Fibrosis is a pathological tissue repair activity in which many myofibroblasts are activated and extracellular matrix are excessively accumulated, leading to the formation of permanent scars and finally organ failure.
Youliang Zhao +3 more
doaj +1 more source